carmustine has been researched along with Oligodendroglioma in 29 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Oligodendroglioma: A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)
| Excerpt | Relevance | Reference |
|---|---|---|
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 9.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 9.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "In preclinical studies, BCNU, or 1,3-bis(2-chloroethyl)-1-nitrosourea, plus CPT-11 (irinotecan) exhibits schedule-dependent, synergistic activity against malignant glioma (MG)." | 5.11 | Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. ( Affronti, ML; Allen, D; Badruddoja, M; Bigner, DD; Bohlin, C; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Silverman, S; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Irinotecan is a topoisomerase I inhibitor previously shown to be active in the treatment of malignant glioma." | 5.11 | Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. ( Affronti, ML; Allen, D; Bigner, DD; Bohlin, C; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jackson, S; Lentz, C; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Schweitzer, H; Tourt-Uhlig, S; Vredenburgh, J; Walker, A; Ziegler, K, 2004) |
| "Comparative studies were carried out to evaluate the cytotoxic effectiveness of the nitrosureas ACNU (Nimustine) and BCNU (Carmustine) at equitoxic dose levels in xenografts from two astrocytomas grades III/IV (Li, Re) and one oligodendroglioma grade III (Oe) on nude mice." | 3.67 | Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas. ( Bamberg, M; Budach, V; Gerhard, L; Stuschke, M, 1988) |
| "Seventy-nine patients harboring recurrent brain tumors received four cycles of infraophthalmic carotid injections of 160 mg of carmustine." | 2.67 | Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. ( Hager, B; Hannisdal, E; Hirschberg, H; Nome, O; Watne, K, 1992) |
| "Thirteen of 19 (68%) evaluable primary brain tumors and 9 of 16 (56%) evaluable brain metastases responded." | 2.65 | Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary ( Addison, D; Benoit, B; Dennery, J; Grahovac, Z; Hugenholtz, H; Maroun, JA; Peterson, E; Richard, MT; Russell, N; Stewart, DJ, 1984) |
| "Sixty-five patients with malignant brain tumors were treated with a combination of BCNU (100 mg/m2 qd X 1) and procarbazine (100 mg/m2 qd X 14); the cycle was repeated in 1 month and then on a 6-week schedule with procarbazine being given for 21 days." | 2.64 | BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors. ( Boldrey, EB; Crafts, DC; Elashoff, RM; Enot, KJ; Levin, VA; Pischer, TL; Schultz, MJ; Seager, M; Wilson, CB, 1976) |
| "Oligodendroglioma is a rare central nervous system tumor which may occur in pure or mixed histology." | 1.30 | Radiation and chemotherapy improve outcome in oligodendroglioma. ( Allison, RR; Barry, T; Schulsinger, A; Shin, KH; Vongtama, V, 1997) |
| "Positive results were obtained in the treatment of oligodendrogliomas and astrocytomas grade III and IV." | 1.27 | Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations. ( Jaksche, H; Loew, F; Papavero, L, 1987) |
| "Malignant oligodendroglioma is a uniquely chemosensitive glial tumor." | 1.27 | Successful chemotherapy for recurrent malignant oligodendroglioma. ( Cairncross, JG; Macdonald, DR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (48.28) | 18.7374 |
| 1990's | 3 (10.34) | 18.2507 |
| 2000's | 10 (34.48) | 29.6817 |
| 2010's | 2 (6.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glick, JA | 1 |
| Graham, RS | 1 |
| Voils, SA | 1 |
| Nagaiah, G | 1 |
| Almubarak, M | 1 |
| Khan, M | 1 |
| Altaha, R | 1 |
| Durando, X | 2 |
| Lemaire, JJ | 1 |
| Tortochaux, J | 1 |
| Van-Praagh, I | 1 |
| Kwiatkowski, F | 2 |
| Vincent, C | 1 |
| Bailly, C | 1 |
| Verrelle, P | 2 |
| Irthum, B | 1 |
| Chazal, J | 1 |
| Bay, JO | 2 |
| Reardon, DA | 2 |
| Quinn, JA | 2 |
| Rich, JN | 2 |
| Gururangan, S | 2 |
| Vredenburgh, J | 2 |
| Sampson, JH | 2 |
| Provenzale, JM | 2 |
| Walker, A | 2 |
| Badruddoja, M | 1 |
| Tourt-Uhlig, S | 2 |
| Herndon, JE | 2 |
| Dowell, JM | 1 |
| Affronti, ML | 2 |
| Jackson, S | 2 |
| Allen, D | 2 |
| Ziegler, K | 2 |
| Silverman, S | 1 |
| Bohlin, C | 2 |
| Friedman, AH | 2 |
| Bigner, DD | 2 |
| Friedman, HS | 2 |
| Schweitzer, H | 1 |
| Lentz, C | 1 |
| Leuraud, P | 1 |
| Taillandier, L | 1 |
| Medioni, J | 1 |
| Aguirre-Cruz, L | 1 |
| Crinière, E | 1 |
| Marie, Y | 1 |
| Kujas, M | 1 |
| Golmard, JL | 1 |
| Duprez, A | 1 |
| Delattre, JY | 1 |
| Sanson, M | 1 |
| Poupon, MF | 1 |
| Lytle, RA | 1 |
| Jiang, Z | 1 |
| Zheng, X | 1 |
| Rich, KM | 1 |
| Fadeev, BP | 1 |
| Zhabina, RM | 1 |
| Jacques-Olivier, B | 1 |
| Linassier, C | 1 |
| Claude, L | 1 |
| Biron, P | 1 |
| Pierre, B | 1 |
| Xavier, D | 1 |
| Pierre, V | 1 |
| Fabrice, K | 1 |
| Rosti, G | 1 |
| Giovanni, R | 1 |
| Demirer, T | 1 |
| Taner, D | 1 |
| Kobiakov, GL | 1 |
| Stewart, DJ | 1 |
| Grahovac, Z | 1 |
| Benoit, B | 1 |
| Addison, D | 1 |
| Richard, MT | 1 |
| Dennery, J | 1 |
| Hugenholtz, H | 1 |
| Russell, N | 1 |
| Peterson, E | 1 |
| Maroun, JA | 1 |
| Shapiro, WR | 1 |
| Eagan, RT | 1 |
| Dinapoli, RP | 1 |
| Hermann, RC | 1 |
| Groover, RV | 1 |
| Layton, DD | 1 |
| Scott, M | 1 |
| Halperin, EC | 1 |
| Gaspar, L | 1 |
| Imperato, J | 1 |
| Salter, M | 1 |
| Herndon, J | 1 |
| Dowling, S | 1 |
| Allison, RR | 1 |
| Schulsinger, A | 1 |
| Vongtama, V | 1 |
| Barry, T | 1 |
| Shin, KH | 1 |
| Nutt, CL | 1 |
| Noble, M | 1 |
| Chambers, AF | 1 |
| Cairncross, JG | 2 |
| Godard, J | 1 |
| Viennet, G | 1 |
| Raul, JS | 1 |
| Plouvier, E | 1 |
| Miny, J | 1 |
| Jacquet, G | 1 |
| Czorny, A | 1 |
| Levin, VA | 1 |
| Crafts, DC | 1 |
| Wilson, CB | 1 |
| Schultz, MJ | 1 |
| Boldrey, EB | 1 |
| Enot, KJ | 1 |
| Pischer, TL | 1 |
| Seager, M | 1 |
| Elashoff, RM | 1 |
| Paoletti, P | 3 |
| Baldini, M | 1 |
| Knerich, R | 1 |
| Princi, L | 1 |
| Fumagalli, R | 2 |
| Weiss, JF | 1 |
| Pezzotta, S | 2 |
| Racca, AR | 1 |
| Watne, K | 1 |
| Hannisdal, E | 1 |
| Nome, O | 1 |
| Hager, B | 1 |
| Hirschberg, H | 1 |
| Unsgaard, G | 1 |
| Helseth, E | 1 |
| Vik, R | 1 |
| Dalen, A | 1 |
| Stuschke, M | 2 |
| Bamberg, M | 2 |
| Strehl, K | 1 |
| Budach, W | 1 |
| Sprengel, M | 1 |
| Salcman, M | 1 |
| Papavero, L | 1 |
| Loew, F | 1 |
| Jaksche, H | 1 |
| Budach, V | 1 |
| Gerhard, L | 1 |
| Macdonald, DR | 1 |
| Arnold, DL | 1 |
| Shoubridge, EA | 1 |
| Feindel, W | 1 |
| Villemure, JG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative[NCT00031538] | 674 participants (Actual) | Observational | 2002-03-01 | Terminated | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for carmustine and Oligodendroglioma
| Article | Year |
|---|---|
Cerebrospinal fluid leak during treatment with bevacizumab and irinotecan after carmustine-impregnated wafers placement in patients with grade 2 oligodendroglioma and glioblastoma multiforme: report of two cases and review of literature.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[Clinical significance of mustoforan in management of malignant glioma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Astrocytoma; Blood-Brain Barr | 2007 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
The morbidity and mortality of brain tumors. A perspective on recent advances in therapy.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms | 1985 |
7 trials available for carmustine and Oligodendroglioma
| Article | Year |
|---|---|
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Camptothecin; Carmustine; | 2004 |
Intracarotid chemotherapy with a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cis-diaminedichloroplatinum (cisplatin), and 4'-O-demethyl-1-O-(4,6-O-2-thenylidene-beta-D-glucopyranosyl) epipodophyllotoxin (VM-26) in the treatment of primary
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1984 |
Treatment of neuroectodermal brain tumors.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Astrocytoma; Blood-Brain Barrier; Brain Neoplasms; | 1982 |
An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium.
Topics: Adult; Aged; Aged, 80 and over; Astrocytoma; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; | 1993 |
BCNU (NSC-409962) and procarbazine (NSC-77213) treatment for malignant brain tumors.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, C | 1976 |
Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma | 1992 |
19 other studies available for carmustine and Oligodendroglioma
| Article | Year |
|---|---|
Candida meningitis post Gliadel wafer placement successfully treated with intrathecal and intravenous amphotericin B.
Topics: Amphotericin B; Antineoplastic Agents; Candidiasis; Carmustine; Decanoic Acids; Drug Implants; Femal | 2010 |
High-dose BCNU followed by autologous hematopoietic stem cell transplantation in supratentorial high-grade malignant gliomas: a retrospective analysis of 114 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Astrocytoma; Carmustine; Combined Modali | 2003 |
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations.
Topics: Animals; Antineoplastic Agents, Alkylating; Carboplatin; Carmustine; Chromosome Aberrations; Dacarba | 2004 |
BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Brain Neopl | 2004 |
[Combined treatment of glyal and metastatic tumors of the brain].
Topics: Algorithms; Antineoplastic Agents, Alkylating; Astrocytoma; Brain Neoplasms; Carmustine; Combined Mo | 2005 |
Does high-dose carmustine increase overall survival in supratentorial high-grade malignant glioma? An EBMT retrospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Carmustine; Combined Modality Therapy; F | 2007 |
Combination carmustine (BCNU) and dianhydrogalactitol in the treatment of primary brain tumors recurring after irradiation.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Carmustine; Dianhydrogalactitol; Drug Therapy, Combinatio | 1982 |
Radiation and chemotherapy improve outcome in oligodendroglioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine | 1997 |
Differential expression of drug resistance genes and chemosensitivity in glial cell lineages correlate with differential response of oligodendrogliomas and astrocytomas to chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Astrocytes; Astrocytoma; ATP-Binding Cassette Transporte | 2000 |
[Intramedullary spread of a cerebral oligodendroglioma. Two case reports].
Topics: Abducens Nerve Diseases; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 2000 |
Treatment of primitive malignant tumors of the central nervous system. Clinical evaluation of 91 cases.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Ependymoma; Glioma; Humans; Lomustine; Oligodendroglioma | 1979 |
Desmosterol: a biochemical marker of glioma growth.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Chromatography, Gas; Desmosterol; Diagnosis, | 1977 |
Sterols in cerebrospinal fluid during nitrosourea chemotherapy of human brain tumors.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Cholesterol; Desmosterol; Female; Glioma; Humans; I | 1976 |
An isotope agarose assay for rapid testing of the sensitivity of glioma biopsies to chemotherapeutic drugs and biological response modifiers. Effects of BCNU, vincristine, lymphokines and the recombinant agents interferon alpha 2c, interferon gamma and tu
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Biopsy; Carmustine; Cells, Cultured; Child, Prescho | 1988 |
Treatment of high grade glioma xenografts with nitrosoureas in nude mice.
Topics: Animals; Carmustine; Glioblastoma; Glioma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Nimus | 1989 |
Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas. Clinical aspects and critical considerations.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Carotid Arteries; Combined Modality Therapy; Follow-Up Stu | 1987 |
Preliminary experimental results with the nitrosourea derivative ACNU in the treatment of malignant gliomas.
Topics: Animals; Astrocytoma; Carmustine; Disease Models, Animal; Dose-Response Relationship, Drug; Lethal D | 1988 |
Successful chemotherapy for recurrent malignant oligodendroglioma.
Topics: Adult; Antineoplastic Agents; Aziridines; Benzoquinones; Brain Neoplasms; Carmustine; Female; Humans | 1988 |
Metabolic changes in cerebral gliomas within hours of treatment with intra-arterial BCNU demonstrated by phosphorus magnetic resonance spectroscopy.
Topics: Adult; Astrocytoma; Brain Neoplasms; Carmustine; Combined Modality Therapy; Energy Metabolism; Femal | 1987 |